Depending on the severity of hazards involved in the
proposed research, the IBC Chair will determine which of the following
two types of review will be necessary.
Expedited Review
This type of review will be used for low-hazard
research. Examples of this research include, but are not limited
to:
- Work involving only Risk Group 1 biological agents
- Recombinant DNA work that would be considered
exempt from registration according to the NIH
Guidelines
- Recombinant DNA work that would be considered
“Experiments that Require IBC Notice Simultaneous with
Initiation” according to NIH Guidelines
These Protocols will can be reviewed via “Designated Member
Review,” meaning the IBC Chair can designate a single member
to review the Protocol. Alternatively, these Protocols can be
distributed to the full committee for review via email. The
reviewing member(s) will read the application, request more
information as needed, make any comments, and vote for one of
the possible outcomes. If any member feels that more thorough
discussion is necessary, the application will be subject to Full
Committee review.
Full Committee Review
This type of review will be used for higher-hazard
research. Examples of this research include, but are not limited
to:
- Work involving Risk Group 2 and above biological agents
- Recombinant DNA work that would be considered
“Experiments that Require IBC Approval Before
Initiation” according to NIH Guidelines
- Work with human blood or other potentially infectious
materials according to the OSHA Bloodborne Pathogen
standard.
These Protocols will be distributed to the full committee via
email. An IBC meeting may be convened and all members will
discuss the proposed research. Members may request more
information if needed. Upon conclusion of the discussion,
members will vote for one of the possible outcomes.